Enliven Therapeutics Inc
NASDAQ:ELVN
Income Statement
Earnings Waterfall
Enliven Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-83.5m
USD
|
Operating Income
|
-83.5m
USD
|
Other Expenses
|
11.9m
USD
|
Net Income
|
-71.6m
USD
|
Income Statement
Enliven Therapeutics Inc
Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||
Operating Expenses |
(18)
|
(30)
|
(42)
|
(45)
|
(47)
|
(49)
|
(51)
|
(50)
|
(46)
|
(43)
|
(34)
|
(5)
|
(16)
|
(29)
|
(84)
|
|
Selling, General & Administrative |
(4)
|
(7)
|
(10)
|
(11)
|
(12)
|
(12)
|
(13)
|
(11)
|
(9)
|
(9)
|
(15)
|
(12)
|
(16)
|
(17)
|
(19)
|
|
Research & Development |
(14)
|
(23)
|
(32)
|
(33)
|
(36)
|
(37)
|
(38)
|
(38)
|
(36)
|
(34)
|
(19)
|
(28)
|
(35)
|
(47)
|
(65)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
35
|
35
|
35
|
0
|
|
Operating Income |
(18)
N/A
|
(30)
-71%
|
(42)
-38%
|
(45)
-7%
|
(47)
-6%
|
(49)
-2%
|
(51)
-6%
|
(50)
+3%
|
(46)
+8%
|
(43)
+6%
|
(34)
+20%
|
(5)
+86%
|
(16)
-240%
|
(29)
-85%
|
(84)
-187%
|
|
Pre-Tax Income | ||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
6
|
9
|
12
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
35
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
|
Pre-Tax Income |
(17)
N/A
|
(30)
-71%
|
(41)
-39%
|
(44)
-7%
|
(47)
-7%
|
(49)
-3%
|
(51)
-6%
|
(50)
+3%
|
(46)
+9%
|
(42)
+7%
|
2
N/A
|
(2)
N/A
|
(10)
-414%
|
(20)
-105%
|
(72)
-259%
|
|
Net Income | ||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(17)
|
(30)
|
(41)
|
(44)
|
(47)
|
(49)
|
(51)
|
(50)
|
(46)
|
(42)
|
1
|
(2)
|
(10)
|
(20)
|
(72)
|
|
Net Income (Common) |
(25)
N/A
|
(38)
-49%
|
(49)
-31%
|
(44)
+10%
|
(47)
-7%
|
(49)
-3%
|
(51)
-6%
|
(50)
+3%
|
(46)
+9%
|
(42)
+7%
|
1
N/A
|
(2)
N/A
|
(10)
-397%
|
(20)
-104%
|
(72)
-258%
|
|
EPS (Diluted) |
-5.87
N/A
|
-8.68
-48%
|
-14.14
-63%
|
-10.11
+29%
|
-10.69
-6%
|
-7.81
+27%
|
-9.49
-22%
|
-16.32
-72%
|
-14.68
+10%
|
-13.13
+11%
|
0.23
N/A
|
-0.1
N/A
|
-0.23
-130%
|
-0.48
-109%
|
-2.01
-319%
|